

# Molecular docking analysis of candidate compounds derived from medicinal plants with type 2 diabetes mellitus targets

Pratistha Singh<sup>1,\*</sup>, Vinay Kumar Singh<sup>2</sup>, Anil Kumar Singh<sup>1</sup>

<sup>1</sup>Department of Dravyaguna, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India; <sup>2</sup>Centre for Bioinformatics, School of Biotechnology, Institute of Science, Banaras Hindu University, Varanasi, India; Pratistha Singh - E-mail: psingh30.bhu@gmail.com; \*Corresponding author

Received January 16, 2019; Revised February 13, 2019; Accepted February 15, 2019; Published March 15, 2019

DOI:10.6026/97320630015179

## Abstract:

Herbal drugs are used for the treatment of diseases and disorders with its less side effects, easy availability and low cost. Several bioactive compounds have been isolated from medicinal plants such as *Ficus benghelensis*, *Ficus racemosa*, *Ficus religiosa*, *Thespesia populena* and *Ficus lacur bouch* were taken for screening. This study aimed to evaluate molecular interactions of selected diabetes mellitus (DM) targets with bioactive compounds isolated from *Ficus benghelensis*, *Ficus racemosa*, *Ficus religiosa*, *Thespesia populena* and *Ficus lacur bouch*. In this article, screening of the best substances as bioactive compounds is achieved by molecular docking analysis with 3 best selected DM target proteins i.e., aldose reductase (AR), Insulin Receptor (IR) and Mono-ADP ribosyltransferase-sirtuin-6 (SIRT6). In this analysis six potential bioactive compounds (gossypetin, herbacetin, kaempferol, leucoperalgonidin, leucodelphinidin and sorbifolin) were successfully identified on the basis of binding energy (>8.0 kcal/mol) and dissociation constant using YASARA. Out of six compounds, herbacetin and sorbifolin were observed as most suitable ligands for management of diabetes mellitus.

**Keywords:** Diabetes mellitus; *in silico* docking; aldose reductase; insulin receptor; SIRT-6; medicinal plants

## Background:

Incidence of Diabetes Mellitus (DM) is increasing every day among every population of the world. Conferring to a report by International Diabetes Federation (2011), there are 366 million people presently suffering from DM and it would up surge to 552 million till 2030. In 2000, the pervasiveness of Type 2 Diabetes Mellitus worldwide among adults was projected to be approximately 171 million [1] whereas in 2015 this number raised up to around 415 million [2]. Diabetes Mellitus is a cluster of metabolic disorder, an illness of hyperglycemia in which person grieves from disorders like failure of pancreas to produce insulin or insensitivity of cells towards insulin (insulin resistance). Diabetes Mellitus (DM) was previously called as "Non-insulin dependent diabetes mellitus" (NIDDM) [3]. Principal symptoms of DM are polyuria (recurrent urination), polydipsia (augmented thirst) and polyphagia (amplified hunger). Common explanations of Type 2 DM are lifestyle changes, obesity (defined as body mass index

greater than 30), absence of physical activity, extreme body weight, deprived diet and anxiety [4]. There are numerous synthetic drugs available such as meglitinides, biguanides, sulfonylureas, thiazolidinediones,  $\alpha$ -glucosidase inhibitors, dipeptidyl peptidase-IV inhibitors for treatment of DM [5, 34]. Today, researchers emphases primarily on finding of effective, low side effect and innocent therapeutic drugs to treat of DM [6]. Medicinal plants contain chemical groups (e.g., Phenolic acids, Flavonoids, Triterpenoids, Alkaloids and Carbohydrates) that hold strong anti-diabetic properties, which can normalize blood glucose level. In traditional medicine, numerous medicinal plants were used such as *Ficus benghalensis* (Banyana), *Ficus religiosa* (Peepal), *Ficus racemosa* (Gular), *Thespesia populnea*, (Paras peepal) and *Ficus lacorbuch* (Pakar) that avoid difficulties in organization of Diabetes Mellitus.

There are a number of targets in the form of receptors are selected for treatment of DM such as Aldose Reductase (AR), Insulin Receptor (IR) and Sirtuin-6 or Mono-ADP ribosyltransferase-sirtuin-6 (SIRT6). Many more are still under exploring study to alleviate DM. AR (EC 1.1.1.21) is a monomeric, NADP-dependent oxidoreductase enzyme and a member of aldo-keto reductase multigene superfamily. Study presented that an upsurge in AR (aldose reductase) activity leads to an enlarged accumulation of intercellular sorbitol which outcomes in boosted complication in DM [7]. Another receptor called IR (Insulin receptor) which belongs to class of tyrosinekinase, a trans membrane receptor [8]. One of the most common causes DM is inactivation of insulin receptor function [9]. IR is activated by insulin, IGF-1 (Insulin-like growth factor) and IGF-II (Insulin growth factor-II) and any inequity in production or response of these factors adds to a cause in DM [10]. Mono-ADP ribosyltransferase-sirtuin-6 (SIRT6) or Sirtuin-6 is a stress receptive protein deacetylase and mono-ADP ribosyl transferase enzyme programmed by the SIRT-6 gene. SIRT-6 plays role in numerous molecular pathways such as aging, including DNA repair, telomere maintenance, glycolysis and inflammation. Sirtuin-6 is a possible therapeutic target for DM [11].

#### Materials AND Methods:

##### Receptors:

A major database CDD Conserved Domains Database in area of structural biology and computational biology for research and education [12,13]. The three-dimensional crystal structure taken

form Protein Data Bank (PDB) ie., AR (PDB ID:1US0) [14] IR (PDB ID:1IR3) [14] SIRT-6 (PDB ID: 3K35) [15] (Figure 1).

##### Active site identification:

CDD BLAST [12] and Metapocket (<http://projects.biotech.tu-dresden.de/metapocket/>) server were used for identification of probable active sites. Discovery Studio 3.0 developed by Accelrys, used for visualization of three-dimensional complex structures and active site residues visualization (<http://accelrys.com/>).

##### Ligands retrieval and assessment:

For ligand retrieval and assessment used Lipinski filter free online server services for retrieval of important molecular properties of bioactive compounds such as cLogp, hydrogen bond donors/acceptor and Molar refractivity [16]. Lipinski's rule of five were applied for selection of ligands and ADEM-TOX -Drug3 (Free ADME-Tox Tool version 3.0) used for computational prediction of Adsorption, Distribution, Metabolism, Excretion, and Toxicity properties [17].

##### Docking calculation and visualization:

YASARA Autodock VINA tool, Yet another Scientific Artificial Reality Application (YASARA) was used for docking calculation. It is an online software for molecular graphics, modeling and simulation [18]. The docking analyses of potent ligands were visualized using Discovery Studio 3.0. Interactions were calculated on the basis of binding energy and containing receptor residues (Kcal/mol).




Figure 1: 3-D Structure of AR (PDB ID: 1US0), IR (PDB ID: 1IR3) and SIRT-6 (PDB ID: 3K35) visualized by Discovery Studio 3.0



**Table 3:** Drug Likeness using Lipinski's rule

S. No.	Compounds	Molecular mass less than 500	Hydrogen bond donor less than 5 hydrogen bond donors	Hydrogen bond acceptor less than 10 hydrogen bond acceptors	LOGP High lipophilicity expressed as log P less than 5	Molar refractivity less should be between 40-130	Status
1.	6-heptatriacontene-10-one	532.000	0	1	13.634	173.239	Not accepted
2.	Pentatriacontan-5-one	506.000	0	1	13.078	164.099	Not accepted
3.	Meso-inositol	180.000	6	6	-3.835	36.041	Not accepted
4.	Leucoperalgonidin	290.000	5	6	1.331	72.214	Accepted
5.	Leucocyanidin	306.000	6	7	1.037	73.879	Not accepted
6.	leucodelphinidin	322.000	7	8	0.743	75.543	Accepted
7.	$\alpha$ -amyrin	428.000	1	1	8.105	130.674	Not accepted
8.	Lupeol	426.000	1	1	8.025	130.649	Not accepted
9.	Stigmasterol	412.000	1	1	7.800	128.123	Not accepted
10.	Lanosterol	426.000	1	1	8.479	132.879	Not accepted
11.	Octacosanol	410.000	1	1	10.141	132.802	Not accepted
12.	Methyl oleonate	296.000	0	2	6.197	91.467	Not accepted
13.	Lupen-3- one	312.000	5	6	-0.053	77.146	Not accepted
14.	Campesterol	400.000	1	1	7.635	123.599	Not accepted
15.	Hentriacontane	436.000	0	0	12.339	145.241	Not accepted
16.	Hentriacontanol	452.000	1	1	11.311	146.653	Not accepted
17.	Kaempferol	286.000	4	6	2.305	72.386	Accepted
18.	Glauanol	428.000	0	2	7.793	126.509	Accepted
19.	Esters of taraxasterol	428.000	1	1	8.105	130.674	Not Accepted
20.	Lupeolacetate	468.000	0	2	8.596	140.197	Not accepted
21.	Friedelin	426.000	0	1	8.457	129.744	Not accepted
22.	Cycloartenol	426.000	1	1	8.169	130.719	Not accepted
23.	Euphorbol	440.000	1	1	8.725	137.426	Not accepted
24.	Hexacosanoate	424.000	0	2	9.932	133.115	Not accepted
25.	Taraxerone	424.000	0	1	8.377	129.719	Not accepted
26.	Tinyatoin	598.000	2	8	4.736	160.141	Not accepted
27.	Leucoanthocyanidin	242.000	2	3	2.215	67.219	Accepted
28.	Herbactin	302.000	5	40	2.011	74.050	Accepted
29.	Gossypol	518.000	6	8	3.846	139.167	Not accepted
30.	Populneol	242.000	1	3	3.174	3.174	Accepted
31.	Calycapterin	374.000	2	8	2.714	94.757	Accepted
32.	Thespesone	257.000	0	4	2.141	68.630	Accepted
33.	Thespone	240.000	0	3	3.218	68.676	Accepted
34.	Gossypetin	318.000	6	8	1.716	75.715	Accepted
35.	Triterpenoides	550.000	1	7	5.437	140.072	Not accepted
36.	$\beta$ amyrin	426.000	1	1	8.169	130.719	Not accepted
37.	Bergenin	328.000	5	9	-1.201	72.240	Not accepted
38.	Caffeic acid	179.000	2	4	-0.139	43.812	Not accepted
39.	Methyl ricinolate	312.000	1	3	5.168	92.858	Accepted
40.	Scutellarein	461.000	6	12	-1.644	103.130	Not accepted
41.	Sorbifolin	300.000	3	6	2.428	77.366	Accepted
42.	Bergapten	216.000	0	4	2.373	57.435	Accepted
43.	Bergaptnol	202.000	1	4	2.071	52.548	Accepted

**Table 4:** FAF Drug Results: Best selected compounds on the basis of adsorption, distribution, metabolism, excretion and toxicity.

S. N.	Compound Name	Heavy atom	Hetero atom	Solubility (mg/L)	Oral (Bioavailability) (EGAN)	Oral (Bioavailability) (VEBER)	Ratio (H/C)	3-75	Status
1.	Leucoperalgonidin	21	6	30803.51	Good	Good	0.40	Good	Accepted
2.	Leucodelphinidin	23	8	444470.47	Good	Good	0.53	Good	Accepted
3.	Kaempferol	21	6	12543.68	Good	Good	0.40	Good	Accepted
4.	Leucoanthocyanidin	18	3	17228.74	Good	Good	0.20	Warning	Accepted
5.	Herbactin	22	7	10239.43	Good	Good	0.46	Good	Accepted
6.	Populneol	18	3	7959.60	Good	Good	0.20	Bad	Accepted
7.	Calycapterin	27	8	6459.43	Good	Good	0.42	Warning	Accepted
8.	Thespesone	19	4	15936.11	Good	Good	0.27	Warning	Accepted
9.	Thespone	18	3	7740.16	Good	Good	0.20	Warning	Accepted
10.	Gossypetin	23	15	12386.97	Good	Good	0.53	Good	Accepted
11.	Methyl ricinolate	22	3	3645.68	Good	Good	0.16	Bad	Accepted

12.	Sorbifolin	22	6	6706.61	Good	Good	0.38	Good	Accepted
13.	Bergapten	16	4	14084.11	Good	Good	0.33	Warning	Accepted
14.	Bergaptnol	15	4	15635.88	Good	Good	0.36	Warning	Accepted

**Table 5:** YASARA Docking Calculation: Binding Energy (Kcal/mol) of receptors and ligands complexes.

S.N.	Compound Name (CID NO.)	AR	IR	SIRT-6
1.	Gossypetin(5280647)	000008.006	000008.429	000008.569
2.	Herbacetin (5280544)	000009.623	000008.165	000008.632
3.	Kaempferol (5280863)	000010.034	000007.881	000008.533
4.	Leucodelphinidin (440835)	000008.012	000007.915	000008.234
5.	Leucoperalgonidin (3286789)	000009.020	000007.756	000007.874
6.	Sorbifolin (3084390)	000009.391	000008.063	000008.697

**Table 6:** Interacted, Reported, Predicted active site residues of AR and compounds.

s. No.	Compound Name	Interacted Residues	Reported Active Site Residues	Predicted Active Site Residues	Common Residues
1	Gossypetin	Trp <sup>20</sup> , Val <sup>47</sup> , Tyr <sup>48</sup> , Gln <sup>49</sup> , Trp <sup>79</sup> , His <sup>110</sup> , Trp <sup>111</sup> , Phe <sup>115</sup> , Phe <sup>122</sup> , Phe <sup>115</sup> , Phe <sup>122</sup> , Trp <sup>219</sup> , Cys <sup>299</sup> , Ala <sup>299</sup> , Leu <sup>300</sup> , Cys <sup>303</sup> , Tyr <sup>309</sup> , Phe <sup>311</sup>	Gly <sup>18</sup> , Thr <sup>19</sup> , Trp <sup>20</sup> , Ile <sup>35</sup> , Tyr <sup>48</sup> , Lys <sup>202</sup> , His <sup>110</sup> , Trp <sup>111</sup> , Ser <sup>159</sup> , Asn <sup>160</sup> , Gln <sup>183</sup> , Tyr <sup>209</sup> , Ser <sup>210</sup> , Pro <sup>211</sup> , Leu <sup>212</sup> , Gly <sup>213</sup> , Ser <sup>214</sup> , Ala <sup>208</sup> , Ile <sup>260</sup> , Pro <sup>261</sup> , Lys <sup>262</sup> , Ser <sup>263</sup> , Glu <sup>271</sup> , Asn <sup>272</sup> , Phe <sup>273</sup>	Trp <sup>20</sup> , Lys <sup>21</sup> , Pro <sup>218</sup> , Trp <sup>219</sup> , Trp <sup>29</sup> , Cys <sup>80</sup> , Trp <sup>111</sup> , Thr <sup>113</sup> , Phe <sup>115</sup> , Phe <sup>122</sup> , Leu <sup>300</sup> , Cys <sup>303</sup> , Tyr <sup>309</sup> , Ala <sup>299</sup> , Cys <sup>298</sup> , His <sup>110</sup> , Val <sup>47</sup> , Tyr <sup>48</sup> , Asn <sup>160</sup> , Tyr <sup>209</sup> , Ser <sup>159</sup> , Gln <sup>183</sup> , Ser <sup>210</sup> , Lys <sup>77</sup> , Asp <sup>143</sup> , Ile <sup>260</sup> , Thr <sup>19</sup> , Gly <sup>18</sup> , Lys <sup>262</sup> , Ser <sup>214</sup> , Pro <sup>211</sup> , Asp <sup>216</sup> , Leu <sup>212</sup> , Pro <sup>215</sup> , Pro <sup>261</sup> , Leu <sup>228</sup> , Arg <sup>268</sup> , Ser <sup>263</sup> , Asn <sup>272</sup> , Ala <sup>245</sup> , Glu <sup>271</sup> , Thr <sup>243</sup> , Thr <sup>244</sup> , Glu <sup>229</sup> , Ser <sup>226</sup> , Val <sup>264</sup> , Thr <sup>265</sup> , Val <sup>297</sup> , Ser <sup>302</sup> , Leu <sup>124</sup> , Leu <sup>301</sup> , Phe <sup>111</sup> , Pro <sup>310</sup> , Gln <sup>49</sup> , Phe <sup>121</sup> , His <sup>46</sup> , Leu <sup>108</sup> , Val <sup>130</sup> , Gly <sup>213</sup> , Glu <sup>267</sup> , Asn <sup>50</sup> , Ser <sup>22</sup>	Trp <sup>20</sup> , Tyr <sup>48</sup> , His <sup>110</sup> , Trp <sup>111</sup>
2	Herbacetin	Trp <sup>20</sup> , Val <sup>47</sup> , Tyr <sup>48</sup> , Trp <sup>79</sup> , Cys <sup>80</sup> , His <sup>110</sup> , Trp <sup>111</sup> , Thr <sup>113</sup> , Phe <sup>115</sup> , Phe <sup>122</sup> , Trp <sup>219</sup> , Cys <sup>298</sup> , Ala <sup>299</sup> , Leu <sup>300</sup> , Cys <sup>303</sup> , Tyr <sup>309</sup> , Pro <sup>310</sup> , Phe <sup>311</sup>			Trp <sup>20</sup> , Tyr <sup>48</sup> , His <sup>110</sup> , Trp <sup>111</sup>
3	Kaempferol,	Trp <sup>20</sup> , Val <sup>47</sup> , Tyr <sup>48</sup> , Trp <sup>79</sup> , Cys <sup>80</sup> , His <sup>110</sup> , Trp <sup>111</sup> , Thr <sup>113</sup> , Phe <sup>115</sup> , Phe <sup>122</sup> , Trp <sup>219</sup> , Cys <sup>298</sup> , Ala <sup>299</sup> , Leu <sup>300</sup> , Cys <sup>303</sup> , Tyr <sup>309</sup> , Pro <sup>310</sup> , Phe <sup>311</sup>			Trp <sup>20</sup> , Tyr <sup>48</sup> , His <sup>110</sup> , Trp <sup>111</sup>
4	Leucodelphinidin	Trp <sup>20</sup> , Val <sup>47</sup> , Tyr <sup>48</sup> , Gln <sup>49</sup> , Lys <sup>77</sup> , Trp <sup>79</sup> , His <sup>110</sup> , Trp <sup>111</sup> , Phe <sup>122</sup> , Asn <sup>160</sup> , Gln <sup>183</sup> , Tyr <sup>209</sup> , Ser <sup>210</sup> , Trp <sup>219</sup> , Trp <sup>20</sup> , Val <sup>47</sup> , Tyr <sup>48</sup> , Trp <sup>79</sup> , Cys <sup>80</sup> , His <sup>110</sup> , Trp <sup>111</sup> , Thr <sup>113</sup> , Phe <sup>115</sup> , Phe <sup>122</sup> , Trp <sup>219</sup> , Cys <sup>298</sup> , Ala <sup>299</sup> , Leu <sup>300</sup> , Cys <sup>303</sup> , Tyr <sup>309</sup> , Pro <sup>310</sup> , Phe <sup>311</sup> , Cys <sup>298</sup> , Leu <sup>300</sup>			Trp <sup>20</sup> , Tyr <sup>48</sup> , His <sup>110</sup> , Trp <sup>111</sup>
5	Leucoperalgonidin	Trp <sup>20</sup> , Val <sup>47</sup> , Tyr <sup>48</sup> , Trp <sup>79</sup> , Cys <sup>80</sup> , His <sup>110</sup> , Trp <sup>111</sup> , Thr <sup>113</sup> , Phe <sup>115</sup> , Phe <sup>122</sup> , Trp <sup>219</sup> , Cys <sup>298</sup> , Ala <sup>299</sup> , Leu <sup>300</sup> , Cys <sup>303</sup> , Tyr <sup>309</sup> , Phe <sup>311</sup>			TRP <sup>20</sup> , Tyr <sup>48</sup> , His <sup>110</sup> , Trp <sup>111</sup>
6	Sorbifolin	Trp <sup>20</sup> , Val <sup>47</sup> , Tyr <sup>48</sup> , Trp <sup>79</sup> , Cys <sup>80</sup> , His <sup>110</sup> , Trp <sup>111</sup> , Thr <sup>113</sup> , Phe <sup>115</sup> , Phe <sup>122</sup> , Pro <sup>218</sup> , Trp <sup>219</sup> , Ala <sup>299</sup> , Leu <sup>300</sup> , Cys <sup>303</sup> , Tyr <sup>309</sup> , Pro <sup>310</sup>			TRP <sup>20</sup> , Tyr <sup>48</sup> , His <sup>110</sup> , Trp <sup>111</sup>

**Table 7:** Interacted, Reported, Predicted active site residues of IR and compounds.


S. N.	Compound name	Interacted Residues	Reported Active Site Residues	Predicted Active Site Residues	Common Residues
1.	Gossypetin	Leu <sup>1002</sup> , Gly <sup>1005</sup> , Val <sup>1010</sup> , Ala <sup>1028</sup> , Lys <sup>1030</sup> , Glu <sup>1047</sup> , Val <sup>1060</sup> , Met <sup>1076</sup> , Glu <sup>1077</sup> , Leu <sup>1078</sup> , Met <sup>1079</sup> , Gly <sup>1082</sup> , Asp <sup>1083</sup> , Arg <sup>1136</sup> , Asn <sup>1137</sup> , Met <sup>1139</sup> , Asp <sup>1150</sup>	Gly <sup>1005</sup> , Val <sup>1010</sup> , Ala <sup>1028</sup> , Thr <sup>1031</sup> , Glu <sup>1077</sup> , Met <sup>1079</sup> , Asp <sup>1083</sup> , Asp <sup>1132</sup> , Arg <sup>1136</sup> , Asn <sup>1137</sup> , Asp <sup>1150</sup> , Lys <sup>1168</sup> , Gly <sup>1167</sup> , Lys <sup>1168</sup> , Gly <sup>1169</sup> , Leu <sup>1117</sup> , Pro <sup>1172</sup> , Leu <sup>1181</sup> , Lys <sup>1182</sup> , Gly <sup>1184</sup> , Agn <sup>1215</sup>	Arg <sup>1039</sup> , Ile <sup>1042</sup> , Thr <sup>1160</sup> , Arg <sup>1164</sup> , Asp <sup>1161</sup> , Glu <sup>1043</sup> , Arg <sup>1155</sup> , Asn <sup>1046</sup> , Asp <sup>1156</sup> , Ile <sup>1157</sup> , Glu <sup>1040</sup> , Arg <sup>1041</sup> , Gly <sup>1152</sup> , Lys <sup>1165</sup> , Gly <sup>1166</sup> , Val <sup>1185</sup> , Lys <sup>1168</sup> , Gly <sup>1167</sup> , Thr <sup>1154</sup> , Arg <sup>1131</sup> , Val <sup>1129</sup> , Phe <sup>1186</sup> , Gly <sup>1169</sup> , Met <sup>1153</sup> , Thr <sup>1187</sup> , Leu <sup>1170</sup> , Asn <sup>1124</sup> , Lys <sup>1127</sup> , Ser <sup>1037</sup> , Phe <sup>1007</sup> , Leu <sup>1171</sup> , Gly <sup>1184</sup> , Thr <sup>1188</sup> , Lys <sup>1251</sup> , Lys <sup>1030</sup> , Phe <sup>1044</sup> , Glu <sup>1047</sup> , Ala <sup>1048</sup> , Met <sup>1051</sup> , Val <sup>1074</sup> , Met <sup>1076</sup> , Ser <sup>1006</sup> , Glu <sup>1179</sup> , Ser <sup>1189</sup> , Asp <sup>1183</sup> , Pro <sup>1250</sup> , Asp <sup>1150</sup> , Pro <sup>1172</sup> , Phe <sup>1151</sup> , Asp <sup>1132</sup> , Val <sup>1060</sup> , Gly <sup>1149</sup> , Gly <sup>1005</sup> , Val <sup>1010</sup> , Asn <sup>1249</sup> , Asn <sup>1137</sup> , Gln <sup>1004</sup> , Ala <sup>1028</sup> , Gly <sup>1008</sup> , Arg <sup>1136</sup> , Glu <sup>1077</sup>	Gly <sup>1005</sup> , Asn <sup>1137</sup> , Leu <sup>1002</sup> , Asp <sup>1150</sup> , Asp <sup>1083</sup> , Asn <sup>1137</sup> , Met <sup>1079</sup> , Arg <sup>1136</sup>

				Met <sup>1139</sup> , Gly <sup>1003</sup> , Leu <sup>1078</sup> , Met <sup>1079</sup> , Leu <sup>1002</sup> , Val <sup>1173</sup> , Asp <sup>1083</sup> , Ala <sup>1080</sup> , Gly <sup>1082</sup> , His <sup>1081</sup> , Ser <sup>1086</sup> , Lys <sup>1085</sup> , Arg <sup>1000</sup> , Glu <sup>1001</sup> , Glu <sup>1012</sup> , Tyr <sup>1087</sup> , Asn <sup>1097</sup> , Ser <sup>1090</sup> , Pro <sup>1099</sup> , Leu <sup>1133</sup> , Ala <sup>1134</sup> , Trp <sup>1175</sup> , Ser <sup>1194</sup> , Arg <sup>1174</sup> , Asn <sup>1215</sup> , Gln <sup>1208</sup> , His <sup>1130</sup>	
2.	Herbacetin	Leu <sup>1002</sup> , Gly <sup>1005</sup> , Val <sup>1010</sup> , Ala <sup>1028</sup> , Lys <sup>1030</sup> , Glu <sup>1047</sup> , Val <sup>1060</sup> , Met <sup>1076</sup> , Glu <sup>1077</sup> , Leu <sup>1078</sup> , Met <sup>1079</sup> , Ala <sup>1080</sup> , Gly <sup>1082</sup> , Asp <sup>1083</sup> , Arg <sup>1136</sup> , Asn <sup>1137</sup> , Met <sup>1139</sup> , Asp <sup>1150</sup>			Gly <sup>1005</sup> , Asn <sup>1137</sup> , Leu <sup>1002</sup> , Asp <sup>1150</sup> , Asp <sup>1083</sup> , Asn <sup>1137</sup> , Met <sup>1079</sup> , Arg <sup>1136</sup>
3.	Kaempferol	Leu <sup>1002</sup> , Val <sup>1010</sup> , Ala <sup>1028</sup> , Lys <sup>1030</sup> , Glu <sup>1047</sup> , Val <sup>1060</sup> , Met <sup>1076</sup> , Glu <sup>1077</sup> , Leu <sup>1078</sup> , Met <sup>1079</sup> , Ala <sup>1080</sup> , Gly <sup>1082</sup> , Asp <sup>1083</sup> , Asn <sup>1137</sup> , Met <sup>1139</sup> , Asp <sup>1150</sup>			Asn <sup>1137</sup> , Leu <sup>1002</sup> , Asp <sup>1150</sup> , Asp <sup>1083</sup> , Asn <sup>1137</sup> , Met <sup>1079</sup>
4.	Leucodelphinidin	Leu <sup>1002</sup> , Gly <sup>1003</sup> , Gly <sup>1005</sup> , Ser <sup>1006</sup> , Val <sup>1010</sup> , Ala <sup>1028</sup> , Lys <sup>1030</sup> , Met <sup>1076</sup> , Glu <sup>1077</sup> , Leu <sup>1078</sup> , Met <sup>1079</sup> , Gly <sup>1082</sup> , Asp <sup>1083</sup> , Arg <sup>1136</sup> , Asn <sup>1137</sup> , Met <sup>1139</sup> , Asp <sup>1150</sup>			Gly <sup>1005</sup> , Asn <sup>1137</sup> , Leu <sup>1002</sup> , Asp <sup>1150</sup> , Asp <sup>1083</sup> , Met <sup>1079</sup> , Arg <sup>1136</sup>
5.	Leucoperalgonidin	Leu <sup>1002</sup> , Gly <sup>1003</sup> , Val <sup>1010</sup> , Ala <sup>1028</sup> , Lys <sup>1030</sup> , Glu <sup>1047</sup> , Val <sup>1060</sup> , Met <sup>1076</sup> , Glu <sup>1077</sup> , Leu <sup>1078</sup> , Met <sup>1079</sup> , Ala <sup>1080</sup> , Gly <sup>1082</sup> , Asp <sup>1083</sup> , Met <sup>1139</sup> , Gly <sup>1149</sup> , Asp <sup>1150</sup> , Phe <sup>1151</sup>			Leu <sup>1002</sup> , Asp <sup>1150</sup> , Asp <sup>1083</sup> , Met <sup>1079</sup>
6.	Sorbifolin	Leu <sup>1002</sup> , Gln <sup>1004</sup> , Gly <sup>1005</sup> , Val <sup>1010</sup> , Ala <sup>1028</sup> , Lys <sup>1030</sup> , Glu <sup>1047</sup> , Val <sup>1060</sup> , Met <sup>1076</sup> , Glu <sup>1077</sup> , Leu <sup>1078</sup> , Met <sup>1079</sup> , Ala <sup>1080</sup> , Gly <sup>1082</sup> , Met <sup>1139</sup> , Asp <sup>1150</sup>			Leu <sup>1002</sup> , Gly <sup>1105</sup> , Met <sup>1079</sup> , Asp <sup>1150</sup>

**Table 8:** Interacted, Reported, Predicted active site residues of 3k35 and compounds.

S.N	Compound name	Interacted Residues	Reported Active Site Residues	Predicted Active Site Residues	Common Residues
1.	Gossypetin	Lys <sup>13</sup> , Gly <sup>50</sup> , Ala <sup>51</sup> , Phe <sup>62</sup> , Arg <sup>63</sup> , Trp <sup>69</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , Val <sup>113</sup> , His <sup>131</sup> , Trp <sup>186</sup> , Leu <sup>190</sup> , Gly <sup>212</sup> , Thr <sup>213</sup> , Ser <sup>214</sup> , Ile <sup>217</sup>	Gly <sup>52</sup> , Ser <sup>54</sup> , Thr <sup>55</sup> , Phe <sup>62</sup> , Arg <sup>63</sup> , His <sup>93</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , Asp <sup>114</sup> , Gly <sup>212</sup> , Ile <sup>217</sup> , Leu <sup>239</sup> , Gln <sup>240</sup> , Gly <sup>254</sup> , Tyr <sup>255</sup>	Val <sup>68</sup> , Trp <sup>69</sup> , Glu <sup>72</sup> , Pro <sup>78</sup> , Phe <sup>62</sup> , Trp <sup>186</sup> , Met <sup>155</sup> , Asp <sup>185</sup> , Leu <sup>184</sup> , His <sup>66</sup> , Met <sup>71</sup> , Lys <sup>79</sup> , Ala <sup>77</sup> , Pro <sup>60</sup> , Phe <sup>80</sup> , Lys <sup>13</sup> , Arg <sup>63</sup> , Gly <sup>156</sup> , Ile <sup>217</sup> , Glu <sup>187</sup> , Gly <sup>67</sup> , Ile <sup>183</sup> , Asp <sup>81</sup> , Gly <sup>64</sup> , Pro <sup>65</sup> , Asp <sup>61</sup> , Asp <sup>188</sup> , Glu <sup>20</sup> , Phe <sup>84</sup> , Met <sup>134</sup> , Arg <sup>218</sup> , Gly <sup>58</sup> , Ile <sup>59</sup> , Thr <sup>25</sup> , Gln <sup>240</sup> , Lys <sup>15</sup> , Ser <sup>214</sup> , Val <sup>113</sup> , Gln <sup>216</sup> , His <sup>131</sup> , Ser <sup>189</sup> , Leu <sup>190</sup> , Leu <sup>18</sup> , Leu <sup>239</sup> , Ala <sup>51</sup> , Pro <sup>219</sup> , Asn <sup>238</sup> , Thr <sup>213</sup> , Leu <sup>215</sup> , Gln <sup>111</sup> , Tyr <sup>255</sup> , Pro <sup>241</sup> , Gly <sup>52</sup> , Gly <sup>212</sup> , Ser <sup>220</sup> , Ser <sup>57</sup> , Ala <sup>56</sup> , Phe <sup>22</sup> , Asp <sup>114</sup> , Asn <sup>112</sup> , Gly <sup>50</sup> , Gly <sup>221</sup> , Ser <sup>54</sup> , Gly <sup>115</sup> , Thr <sup>49</sup> , Gly <sup>254</sup> , Val <sup>237</sup> , Val <sup>256</sup> , Ile <sup>53</sup> , Asp <sup>257</sup> , Thr <sup>90</sup> , Glu <sup>258</sup>	Phe <sup>62</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , Gly <sup>212</sup> , Ile <sup>217</sup>
2.	Herbacetin	Lys <sup>13</sup> , Gly <sup>50</sup> , Ala <sup>51</sup> , Phe <sup>62</sup> , Arg <sup>63</sup> , Trp <sup>69</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , Val <sup>113</sup> , His <sup>131</sup> , Trp <sup>186</sup> , Thr <sup>213</sup> , Ser <sup>214</sup> , Leu <sup>215</sup> , Gln <sup>216</sup> , Ile <sup>217</sup>			Phe <sup>62</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , Ile <sup>217</sup>
3.	Kaempferol	Lys <sup>13</sup> , Gly <sup>50</sup> , Ala <sup>51</sup> , Gly <sup>52</sup> , Phe <sup>62</sup> , Arg <sup>63</sup> , Trp <sup>69</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , His <sup>131</sup> , Trp <sup>186</sup> , Gly <sup>212</sup> , Thr <sup>213</sup> , Ser <sup>214</sup> , Leu <sup>215</sup> , Gln <sup>216</sup> , Ile <sup>217</sup>			Phe <sup>62</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , Gly <sup>212</sup> , Ile <sup>217</sup>
4.	Leucodelphinidin	Gly <sup>50</sup> , Ala <sup>51</sup> , Phe <sup>62</sup> , Arg <sup>63</sup>			Phe <sup>62</sup> , Gln <sup>111</sup> , Asn <sup>112</sup>

		Trp <sup>69</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , His <sup>131</sup> , Leu <sup>184</sup> , Asp <sup>185</sup> , Trp <sup>186</sup> , Asp <sup>188</sup> , Thr <sup>213</sup> , Ile <sup>217</sup>		Ile <sup>217</sup>
5.	Leucoperalgonidin	Gly <sup>50</sup> , Ala <sup>51</sup> , Phe <sup>62</sup> , Arg <sup>63</sup> , Trp <sup>69</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , His <sup>131</sup> , Leu <sup>184</sup> , Asp <sup>185</sup> , Trp <sup>186</sup> , Asp <sup>188</sup> , Leu <sup>190</sup> , Thr <sup>213</sup> , Ile <sup>217</sup>		Phe <sup>62</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , Ile <sup>217</sup>
6.	Sorbifolin	Lys <sup>13</sup> , Gly <sup>50</sup> , Ala <sup>51</sup> , Gly <sup>52</sup> , Phe <sup>62</sup> , Arg <sup>63</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , Val <sup>113</sup> , His <sup>131</sup> , Il e <sup>183</sup> , Leu <sup>184</sup> , Asp <sup>185</sup> , Trp <sup>186</sup> , Le u <sup>190</sup> , Gly <sup>212</sup> , Thr <sup>213</sup> , Ser <sup>214</sup> , Ile <sup>217</sup>		Phe <sup>62</sup> , Gln <sup>111</sup> , Asn <sup>112</sup> , Gly <sup>212</sup> , Ile <sup>217</sup>




**Figure 2:** 3D structure of herbacetin with AR (PDB ID: 1US0), IR (PDB ID: 1IR3) and SIRT-6 (PDB ID: 3K35)

## Results & Discussion:

From five medicinal plants, 43 bioactive compound and their isolated parts (**Table 1**) were selected for docking calculation. All reported compounds with pubchem CID no, molecular formula, molecular weight, Conical smile (**Table 2**) Lipinski filter server was used to find drug likeness of selected bioactive compounds (**Table 3**). The anti-diabetic compounds that showed good drug likeness properties were further used for computational screening using FAF Drug server 3 (**Table 4**). Total selected compounds as ligand were used for docking calculation with AR, IR, SIRT-6 receptors and docking was performed by YASARA tool. Out of 43 compounds, mainly 6 compounds (Gossypetin, Herbacetin, Kaempferol, Leucodelphinidin, Leucoperalgonidin, Sorbifolin) were observed as best compounds on the basis of Energy (**Table 5**) Docking results obtained for each ligand with the receptor were

analyzed on the basis of docking energy (Kcal/mol) and interaction of each ligand with the functional residues of AR (PDB ID:1USO), IR (PDB ID: 1IR3), SIRT-6 (PDB ID:3K35) (**Figure 1**) with Herbacetin and Sorbifolin respectively (**Figure 2 and Figure 3**). Out of six ligands Herbacetin and Sorbifolin were found best suitable ligands. In docking calculation of AR receptor and 6 ligands Trp20, Tyr48, His110, Trp111 are the most prominent binding residues (**Table 6**) and In case of IR, Leu1002, Met1079, Asp1150 are the most prominent binding residues with 6 ligands (**Table 7**) and In SIRT-6 Phe62, Gln111, Ile217, Asn112 are found to be the most prominent binding sites (**Table 8**). Herbacetin and Sorbifolin were observed most suitable ligands that is found in *Thespesia populnea* and *Ficus lacor buch* respectively. Leucoperalgonidin and Kaempferol were showing best docking with AR, mainly found in *F. benghalensis* and *F. recemosa* respectively.



**Figure 3:** 3D structure of sorbifolin with AR (PDB ID: 1USO), IR (PDB ID: 1IR3) and SIRT-6 (PDB ID: 3K35)



In Ayurvedic literature, Bark of *F. benghalensis*, *F. racemosa*, *F. religiosa*, *T. populnea* and *F.lacor buch* are frequently known as Panchvalkala [33]. *F. benghalensis* is mainly found in India, Bangladesh, Sri Lanka and used to treat diarrhea, dysentery, piles, teeth disorders, rheumatism, skin disorders and diabetes. Bark of *F. benghalensis* has been appraised in numerous animal models by inducing diabetes using alloxan and streptozotocin. It was established that aqueous extract of bark exhibited a strong *in vitro* inhibitory activity against  $\alpha$ -amylase and  $\alpha$ -glucosidase enzymes. The ethanol extract of their leaves successfully reduced the blood glucose, triglycerides and cholesterol levels in alloxan-induced diabetic rats [19–22]. In the traditional systems of medicine, *F. racemosa* is found all over India, Northern Australia and other parts of Asia. In this plant (leaves, fruits, bark, latex, and sap of the root) are used for treatment of diabetes. Mainly bark is used for skin diseases, ulcers, diabetes, piles, dysentery, asthma, gonorrhoea, leucorrhoea and urinary disease. The methanol extract of bark also presented an anti-diabetic effect in Streptozotocin and alloxan-induced diabetic rats [19, 23–27]. *F. religiosa* is mainly found in the sub-himalayan tract, Bengal and central India. It has been commonly used for the treatment of various disorder such as diabetes, atherosclerosis, Alzheimer's disease, gastritis, cancer and AIDS [19, 28–30]. *Thespesia populnea* from Malvaceae family has been reported to possess anti-diabetic compounds. Various experimental findings reveal that *T. populnea* has anti-diabetic properties. Ethanol and aqueous extract of *T. populnea* exhibited noteworthy anti-hyperglycemic and anti-hyperlipidemic effects on alloxan-induced diabetic rats [19, 31, 32]. *Ficus lacor buch* is usually known as Java fig, Pakar or Pakadi. It is found in the temperate climate of India. It is used for treatment of bleeding disorders, herpes, wound, mouth ulcers, diarrhea and leucorrhoea.

#### Conclusion:

AR,IR,SIRT-6 used as prominent target proteins to study the interaction of selected anti-diabetic compounds isolated from various medicinal plants through the *in-silico* screening. A total of 6 anti diabetic compounds were selected out of 43 compounds isolated from five medicinal plants. Based on parameters like good oral bioavailability, Non-toxicity and Drug likeness Adsorption and Distribution, Metabolism, Excretion, Toxicity showing strong binding affinity with prominent binding site residues, only six compounds was selected as the best possible ligands which can be used for treatment of Type 2 Diabetes Mellitus. Leucoperalgonidin and Kaempferol were showing best docking with AR, mainly found in *F. benghalensis*. and *F. racemosa*, respectively.

#### Acknowledgement:

Authors acknowledge the Department of Biotechnology, Government of India, New Delhi for fellowship. The support received from Prof. Arvind Kumar, Coordinator and Center of Bioinformatics, School of Biotechnology, Banaras Hindu University,

Varanasi, India, is a greatly acknowledged for providing software facility and assistance of Information officer Dr. V.K. Singh.

#### References:

- [1] S. Wild *et al.* Diabetes Care. 2004 **27**:1047. [PMID: 15111519]
- [2] K. Ogurtsova *et al.* Diabetes Res. Clin. Pract. 2017 **128**:40–50. PMID: 28437734]
- [3] A.B. Olokoba *et al.* Oman Med. J. 2012 **27**:269. [PMID: 23071876]
- [4] I.-M. Lee *et al.* Lancet (London, England). 2012 **380**:219. [PMID: 22818936]
- [5] R.N. Gacche & N.A. Dhole, Food Chem. Toxicol. 2011 **49**:1806. [PMID: 21570444]
- [6] H. Misbah *et al.* BMC Complement. Altern. Med. 2013 **13**:118. [PMID: 23718315]
- [7] P. Muthenna *et al.* FEBS Lett. 2009 **583**:3637. [PMID: 19850041]
- [8] C.W. Ward, & M.C. Lawrence, Bioessays. 2009 **31**:422. [PMID: 19274663]
- [9] R. Herrera & O.M. Rosen, J. Biol. Chem. 1986 **261**:11980. [PMID: 3745176]
- [10] Y. Ebina *et al.* Cell. 1985 **40**:747 [PMID: 2859121]
- [11] E.J. Bae & Sirtuin 6, Arch. Pharm. Res. 2017 **40**:1380. [PMID: 29177584]
- [12] A. Marchler-Bauer *et al.* Nucleic Acids Res. 2013 **41**:D348–52. [PMID: 25414356]
- [13] R.A. Laskowski *et al.* Trends Biochem. Sci. 1997 **22**:488–490. [PMID: 9433130]
- [14] P. Kaushik, S. *et al.* Adv. Bioinformatics. 2014 **2014**:903246. [PMID: 25114678]
- [15] T.H. Nguyen Vo *et al.* 2016 **5**:1359. [PMCID: PMC4990526]
- [16] C.A. Lipinski *et al.* Adv. Drug Deliv. Rev. 2001 **46**:3. [PMID: 11259830]
- [17] J.G. Cumming *et al.* Nat. Rev. Drug Discov. 2013 **12**:948. [PMID: 24287782]
- [18] E. Krieger, G. Vriend, Bioinformatics. 2014 **30**:2981. [PMID: 24996895]
- [19] P. Deepa *et al.* J. Ethnopharmacol. 2018 **215**:210. [PMID: 29305899]
- [20] D.J. Taur *et al.* Nat. Prod. Res. 2007 **21**:1266.
- [21] M. Gayathri, K. Kannabiran, Indian J. Clin. Biochem. 2008 **23**:394. [PMID: 23105795]
- [22] M. Govindarajan *et al.* Asian Pac. J. Trop. Med. 2011 **4**:505. [PMID: 21803298]
- [23] K. Murti, U. Kumar, Asian Pac. J. Trop. Biomed. 2012 **2**:276. [PMID: 23569913]
- [24] V.P. Veerapur *et al.* Food Chem. 2012 **132**:186. [PMID: 26434279]
- [25] Gul-e-Rana *et al.* Acta Pol. Pharm. 2013 **70**:1045. [PMID: 24383328]
- [26] R. Bhaskara Rao *et al.* Phytother. Res. 2002 **16**:590. [PMID: 12237822]



- [27] N.D. Solanki, S.K. Bhavsar, Indian J. Pharmacol. 2015 **47**:610. [PMID: 26729951]
- [28] D. Singh *et al.* J. Ethnopharmacol. 2011 **134**:565. [PMID: 21296646]
- [29] H. Kirana, S.S. Agrawal, B.P. Srinivasan, Indian J. Exp. Biol. 2009 **47**:822. [PMID: 20112810]
- [30] H. Kirana *et al.* Pharmacognosy Res. 2011 **3**:30. [PMID: 21731392]
- [31] S.N. Belhekar *et al.* Indian J. Pharm. Sci. 2013 **75**:217. [PMID: 24019572]
- [32] M.A. Phanse *et al.* Saudi J. Biol. Sci. 2016 **23**:420. [PMID: 27081369]
- [33] Chuneker, K.C., edited by Pandey G.C., Ayd book. Bhavaprakasha Nighantu. 2000. **15**: 507.
- [34] Sangeetha KN *et al.* Bioinformation. 2017 **(12)**:394. [PMID: 29379255]

Edited by P Kanguane

Citation: Singh *et al.* Bioinformation 15(3): 179-188 (2019)

**License statement:** This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License



Biomedical Informatics Society

Agro Informatics Society



# *Journal*